Dermata Therapeutics (NASDAQ:DRMA) Stock Falls 10.9% – Should You Sell?

Dermata Therapeutics, Inc. (NASDAQ:DRMA)’s stock price dropped 10.9% on Thursday. The company traded as low as $0.7617 and last traded at $0.7619. 49,939 shares changed hands during trading, a decline of 99% from the average session volume of 8,800,836 shares. The stock had previously closed at $0.8548.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dermata Therapeutics in a research note on Monday, October 26th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Dermata Therapeutics Stock Performance

The business has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.29. The company has a market capitalization of $3.79 million, a price-to-earnings ratio of -0.17 and a beta of 0.63.

Dermata Therapeutics (NASDAQ:DRMA) last released its earnings results on Tuesday, August 11th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.19).

About Dermata Therapeutics

Dermata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases. The company’s research is centered on topical therapies intended to address common inflammatory and dermatologic conditions.

Its lead product candidate, DMT310, is a once-weekly topical treatment being evaluated for conditions including psoriasis and acne vulgaris. The therapy is based on a proprietary platform derived from a naturally occurring freshwater sponge and is designed to deliver localized treatment to the skin.